Abbvie

This early-stage study tests an experimental drug called ABBV-706, alone or with other treatments, in adults with advanced solid tumors like small cell lung cancer and brain tumors. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About…

This study gives venetoclax to 165 people with blood cancers like leukemia and lymphoma who already benefited from the drug in earlier studies. The main goal is to track side effects and see how safe the drug is over a longer period. Participants must have tolerated the drug well…

This study tests a new drug called lutikizumab for people with moderate to severe ulcerative colitis, a condition causing colon inflammation and bleeding. About 200 adults will receive either lutikizumab or the standard drug adalimumab to see which works better and is safer. The …

This study looks at how well ABBV-951, a continuous infusion treatment, works over about 3 years for adults with advanced Parkinson's disease. It involves around 427 participants who receive the drug through a pump under the skin. The main goal is to see how much it reduces 'off'…

This study tests an injected drug called risankizumab for adults with moderate-to-severe Crohn's disease, a condition causing painful gut inflammation. About 289 participants will receive either the drug or a placebo for up to 24 weeks, then all may receive the drug for another y…

This program offers early access to the investigational drug ABBV-787 for people with acute myeloid leukemia who have no other treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved by re…

This study follows about 100 adults with acute myeloid leukemia (AML) in Israel who are already prescribed venetoclax by their doctor. Researchers will track how long patients live and how many achieve remission, without giving any new treatments. The goal is to see how well the …

This early-phase trial tests a new drug called IMGN151 in adults with certain gynaecological cancers that have come back. The study aims to find a safe dose and check for side effects. About 256 participants with recurrent endometrial, ovarian, fallopian tube, primary peritoneal,…

This study looks at how well upadacitinib (RINVOQ) controls moderate to severe atopic dermatitis (eczema) over two years in everyday medical practice. About 772 teens and adults in Germany will take the drug as prescribed by their doctor. Researchers will track symptom control an…

This early-stage study tests an experimental drug called etentamig combined with standard treatments for people with multiple myeloma that has returned or stopped responding to therapy. The main goals are to find the safest dose and check for side effects. About 320 adults will t…

This program provides early access to telisotuzumab vedotin, an investigational drug, for people with non-small cell lung cancer who have no other suitable treatment options and cannot join ongoing clinical trials. A doctor must decide if the potential benefits outweigh the risks…

This study tests an experimental drug, telisotuzumab vedotin, in adults with a certain type of advanced lung cancer (c-Met+ non-small cell lung cancer) that has already been treated. The drug works like a guided missile, delivering a toxin directly to cancer cells that have a spe…

This phase 3 study tests whether upadacitinib, a drug already approved for other autoimmune diseases, can safely control moderate-to-severe lupus. About 1,000 adults with lupus will take either the study drug or a placebo daily for a year. The goal is to see if the drug reduces d…

This early-stage study tests an investigational drug called ABBV-400, alone or with another drug (bevacizumab), in about 520 adults with advanced solid tumors including lung, stomach, and colorectal cancers. The goal is to find the safest and most effective dose and see if it can…

This study tests an experimental drug called etentamig (ABBV-383) in about 55 adults with multiple myeloma that has returned or not improved after prior treatments. The drug is given as a shot under the skin or through an IV to see if it can control the cancer. The main goals are…

This study tests an experimental drug injection (AGN-193408 SR) in 100 adults with open-angle glaucoma or high eye pressure. The goal is to see if it safely lowers eye pressure, which is the main way to control these conditions. Participants stop their usual eye drops during the …

This study tests whether the drug risankizumab can help people with ulcerative colitis stay in remission (symptom-free) for a full year. It includes over 1,200 adults who already improved with risankizumab in an earlier study. Participants receive either the drug or a placebo for…

This program gives people with acute spinal cord injury access to the investigational drug elezanumab before it is officially approved. It is only for those who cannot join other clinical trials and have no other good treatment options. A doctor must decide if the possible benefi…

This early-stage study tests an experimental drug called telisotuzumab adizutecan in about 30 Chinese adults with advanced colorectal cancer that cannot be removed by surgery. The main goals are to check safety and how the drug moves through the body. Participants receive differe…

This study tests whether adding the experimental drug navitoclax to standard ruxolitinib can shrink the spleen and ease symptoms in adults with myelofibrosis, a rare blood cancer. About 330 participants whose cancer returned or didn't respond to prior treatment will be randomly a…

This study tests an oral medication called upadacitinib to see if it can safely and effectively restore skin color in people with non-segmental vitiligo, a condition where the immune system attacks pigment cells. About 540 adults and teens will receive either the drug or a placeb…

This early-stage study tests two experimental immunotherapy drugs, ABBV-927 and ABBV-181, in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and understand how the drugs move through the body. About 163 pa…

This study tracks how well risankizumab works for adults recently diagnosed with moderate plaque psoriasis (within the last 2 years) who haven't tried advanced treatments before. About 250 people in Greece will receive the drug as prescribed by their doctor and be observed for up…

This early-phase study tests an experimental drug called ABBV-453 in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to at least two prior treatments. The main goals are to check safety, find the right dose, a…

This study tests a one-time gene therapy called RGX-314 for people with diabetic retinopathy, a leading cause of vision loss. The treatment is given as a single injection behind the eye and aims to reduce the need for frequent eye injections over a lifetime. About 139 adults aged…

This early-stage study tests a new oral drug, ABBV-101, in adults with certain blood cancers (like lymphoma and leukemia) that have returned or stopped responding to standard treatments. The main goals are to check safety and find the right dose. About 340 participants will take …

This study tests whether adding upadacitinib to a steroid taper can prevent relapses in people with Takayasu arteritis, a rare disease that causes inflammation in large blood vessels. About 56 adults who have recently had a relapse despite steroid treatment will receive either up…

This study tests an oral medication called upadacitinib in children aged 2–17 with moderate-to-severe ulcerative colitis who haven't responded to standard treatments. The goal is to see if the drug can reduce inflammation and bring the disease under control. The trial involves an…

This study tests the XEN45 implant, a tiny device placed in the eye to lower pressure in people with open-angle glaucoma. About 120 adults in China will receive either the XEN45 implant or standard surgery, and researchers will track side effects and eye pressure for 5 years. The…

This early-stage study tests an experimental drug called cofetuzumab pelidotin in 65 adults with a specific type of recurrent non-small cell lung cancer (NSCLC) that has a protein called PTK7. The drug is designed to deliver a toxin directly to cancer cells. The main goal is to s…

This study compares two approved drugs, upadacitinib (a pill) and adalimumab (an injection), in adults with moderate to severe rheumatoid arthritis who have already tried one TNF inhibitor without success. About 480 participants will be randomly assigned to one of the two treatme…

This study tests whether a daily pill called upadacitinib can help adults with Crohn's disease stay in remission and prevent symptoms from coming back. About 747 people who already improved on the drug in an earlier study will either continue taking it or switch to a placebo. The…

This study tests a two-step treatment for women whose ovarian, peritoneal, or fallopian tube cancer has returned after initial chemotherapy. First, participants receive a combination of carboplatin (a standard chemo) and mirvetuximab soravtansine (a targeted drug that attacks can…

This early-stage study tests a combination of two drugs, venetoclax and azacitidine, in people with a serious form of myelodysplastic syndromes (MDS) who have not had prior treatment. The goal is to find the safest dose and see how well the drugs work together to control the dise…

This study tests an experimental drug called lutikizumab for adults with moderate-to-severe hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps and scars. The main part of the study includes about 160 people who have already tried and failed anti-TNF the…

This study tests whether a daily pill called upadacitinib, when used with a steroid cream, can safely reduce eczema symptoms like itching and skin redness. About 1,500 teens and adults with moderate-to-severe eczema who need stronger treatment took part. The main goal was to see …

This study tests a drug called lutikizumab for people with moderate to severe atopic dermatitis (eczema). About 80 participants will receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 32 weeks. The goal is to see if it safely reduces skin r…

This study tests a gene therapy called RGX-314 as a potential one-time treatment for wet age-related macular degeneration (nAMD), a leading cause of vision loss. Currently, patients need frequent eye injections to control the disease. The trial involves about 146 adults aged 50-8…

This early-phase study tests a new drug called ABBV-525 in people with B-cell cancers like lymphoma and leukemia. The goal is to check safety and find the best dose. About 78 adults will take the drug by mouth at different dose levels over up to 64 months.

This study tests whether the drug upadacitinib, taken as a pill along with steroid creams, can safely improve moderate-to-severe eczema in children aged 2 to 11 in Japan. About 99 children will be randomly assigned to receive either the drug or a placebo for 12 weeks, then all wi…

This study tests whether adding venetoclax to standard azacitidine helps people with a serious bone marrow disease called higher-risk MDS live longer. About 500 newly diagnosed adults will receive either the drug combo or azacitidine alone. The goal is to control the disease and …

This study tests a new drug called TNB-383B in people with multiple myeloma that has come back or not responded to at least three prior treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to find the safest dose…

This study looks at adults with diabetic macular edema (swelling in the back of the eye) who didn't get enough help from standard anti-VEGF injections. They are given a dexamethasone implant that slowly releases steroid medicine into the eye. Researchers will track how many extra…

This study tests whether risankizumab works better than ustekinumab for adults with moderate to severe Crohn's disease who have not responded to anti-TNF therapy. About 527 participants will receive either drug through IV and injections over a year, with some continuing for up to…

This study tracks 250 adults with advanced Parkinson's disease who are prescribed ABBV-951 by their doctors. The goal is to see how safe and effective the drug is in everyday use over 52 weeks. Participants receive the drug as part of their normal care, with no extra visits requi…

This study tests a new drug called ABBV-400 combined with standard chemotherapy and targeted therapy for adults with advanced colorectal cancer that cannot be removed by surgery. About 280 participants will receive different doses to find the safest and most effective combination…

This program offers early access to the investigational drug fosigotifator for people with vanishing white matter or Cree leukoencephalopathy, rare and serious brain diseases. It is not a clinical trial but a way for eligible patients to receive the drug before it is officially a…

This early-phase study tests an experimental drug called ABBV-400 in about 302 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The main goals are to check safety, side effects, and whether the drug shrinks tumors. Participants receive …

This study tests a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can control the disease and reduce the need for repeated eye injections. About 671 adults a…

This study looks at the long-term safety and effectiveness of a daily pill called upadacitinib for people with ulcerative colitis, a chronic bowel disease causing inflammation and ulcers. About 950 adults who didn't get better with earlier treatments or lost response will take th…

This study follows about 200 adults in Canada with acute myeloid leukemia (AML) who cannot receive intensive chemotherapy. All participants take venetoclax pills daily as part of their routine care. Researchers track survival and remission rates over 36 months to see how well the…

This study tests whether a daily pill called atogepant can prevent migraines that happen around a woman's period. About 468 adult women with regular cycles and a history of migraines will take either atogepant or a placebo for three menstrual cycles. The goal is to see if the dru…

This study tests a gel called ELAPR002f that is injected into the skin to fill in indented acne scars. About 157 adults with moderate to severe scars on both cheeks will receive either the gel or a saltwater placebo over 2 months. Researchers will check if the gel safely improves…

This study tests whether atogepant can quickly relieve migraine attacks in 1300 adults aged 18-75 with a history of migraines. Participants receive either atogepant or a placebo during the first part, then all receive atogepant in the open-label phase. The main goal is to see if …

This study looks at how well the drug foslevodopa-foscarbidopa works for people with advanced Parkinson disease when used in normal medical practice. About 250 adults in France will receive the drug as a continuous infusion under the skin and be followed for up to 12 months. The …

This study tracks safety and satisfaction in 102 people using CoolSculpting Elite to reduce fat in the chin, inner thighs, and back/bra areas without surgery. Participants must have visible fat and stable weight. The goal is to confirm the device's safety and gather user feedback…

This study looks at how satisfied adults are with their facial appearance after receiving JUVÉDERM fillers for volume loss, often seen after medical weight loss. About 75 participants will receive treatment and report their satisfaction using a questionnaire. The goal is to see i…

This study tests whether adding elagolix to birth control pills can better relieve moderate to severe pain from endometriosis. About 800 premenopausal women with surgically confirmed endometriosis will receive either the drug combo or a placebo for 3 months, then all get the acti…

This study looks at how well the migraine drug ubrogepant helps adults in Canada function during and after a migraine attack, and how satisfied they are with the treatment. About 167 participants will take the drug as prescribed by their doctor and be followed for up to 12 weeks.…

This study looks at how people with chronic lymphocytic leukemia (CLL) feel and function while taking different oral treatments. About 146 adults in Spain will fill out questionnaires about their symptoms, fatigue, and worries during routine doctor visits. The goal is to understa…

This study watches about 110 adults with diabetic macular edema who are already receiving OZURDEX implants as part of their normal care in China. Researchers will track side effects and eye health for 24 months after the first dose, plus a 30-day follow-up. No extra treatments or…

This early-stage study in 40 healthy adults aims to understand how the experimental drug ABBV-8736 moves through the body when given as a shot under the skin compared to an infusion into a vein. Researchers will measure the drug's levels in the blood, safety, and any side effects…

This early-stage study looks at how a new drug called ABBV-295 interacts with common birth control pills in healthy adult women who are overweight or obese. The main goal is to check for side effects and measure drug levels in the body. About 20 women will take part to help resea…

This early-stage study tests a single dose of ABBV-701 in about 100 healthy adults from Western and Asian backgrounds. The main goal is to check for side effects and measure how the drug moves through the body. Participants receive either the drug or a placebo, and no direct heal…

This early-stage study is testing a new drug called nacresertib in 96 healthy adults to see if it is safe and how the body handles it. Participants will take either a single dose or multiple doses of the drug. The goal is to gather safety information and measure drug levels in th…

This early-stage study involves 9 healthy adults to see how the body absorbs and processes an experimental drug called ABBV-932. Researchers will measure drug levels in the blood and check if food changes absorption. The goal is to gather information, not to treat any disease.

This study was designed to observe hair loss in women with uterine fibroids who are taking the approved drug Oriahnn. Researchers planned to track how many women experience hair thinning, when it starts, and if it goes away. The study was withdrawn before enrolling any participan…

This study looks at how a drug called itraconazole changes the way ABBV-932 moves through the body. It involves 20 healthy adults who will take both medications. The goal is to check for side effects and measure drug levels in the blood. This is an early-phase study with no direc…

This early-stage study tests a new drug called ABBV-277 in 32 healthy adults for the first time. The main goal is to check its safety and how the body processes it. Participants receive a single dose and are monitored closely. This study does not aim to treat any disease.